FDA Clears Casgevy Gene Therapy for Sickle Cell Patients as Young as 2

The U.S. Food and Drug Administration on July 1 expanded its approval of Casgevy (exagamglogene autotemcel) to cover patients as young as 2 years old with sickle cell disease experiencing recurrent vaso-occlusive crises, as well as children with transfusion-dependent beta thalassemia. According to a press announcement reviewed from GlobeNewswire, the agency had previously cleared the therapy only for patients 12 and older when it first authorized the treatment in 2023.

The expansion, announced by Vertex Pharmaceuticals, makes Casgevy the first and only gene therapy approved for use in that younger age group for either condition. According to Vertex's announcement reviewed by Biospace, the label change extends eligibility to roughly 5,500 additional children in the United States.

Casgevy works by editing a patient's own hematopoietic stem cells outside the body. As described in an FDA press release reviewed on GlobeNewswire, the therapy uses CRISPR/Cas9 gene editing to increase fetal hemoglobin production, which prevents red blood cells from taking on the rigid, crescent shape that blocks blood vessels and triggers pain crises. The edited cells are infused back into the patient after a course of myeloablative chemotherapy clears the bone marrow, a preparatory step that carries its own risks and, as noted by reporting reviewed at TechTimes, includes a permanent infertility risk that families will need to weigh.

The pediatric trial data supporting the expansion were small. According to reporting reviewed at Xtalks, the sickle cell arm enrolled 11 children; of the 8 who could be evaluated for efficacy, all met the primary endpoint, meaning no severe pain crises for at least 12 consecutive months within the first two years after infusion. In the beta thalassemia arm, 15 children were enrolled; of the 9 evaluable patients, 8 achieved transfusion independence for at least a full year, with a median duration of 20.1 months.

Small trial sizes are standard territory for rare pediatric diseases, and regulators noted consistency across age groups in the existing adult data. Still, clinicians managing these patients will want to track long-term durability data as it matures.

The practical question for pediatric hematologists and families is not just efficacy, it's access. According to reporting reviewed at TechTimes, the therapy carries a list price of approximately $2.2 million, and Medicaid coverage gaps remain a live concern for many of the families most likely to need it. Sickle cell disease disproportionately affects Black Americans, and the patient population skews lower-income, making payer decisions at the state Medicaid level a central piece of whether this approval translates to actual treatment.

The conditioning chemotherapy requirement also means treatment can only happen at specialized transplant and cellular therapy centers, which aren't equally distributed across the country. That access bottleneck isn't new to gene therapy, but it lands differently when the candidate is a 2-year-old whose family may need to travel for weeks of inpatient care.

Vertex said in a statement to GlobeNewswire that regulatory review for the expanded label is underway in Saudi Arabia and the United Kingdom. The FDA granted the therapy Orphan Drug, Regenerative Medicine Advanced Therapy, and Fast Track designations, according to a filing reviewed at Respiratory Therapy.

For the roughly 100,000 Americans living with sickle cell disease, most of whom are diagnosed at birth through newborn screening, an earlier intervention window is a meaningful clinical development. The question providers and families will be asking next is who can actually get there.

Sources cited:
- GlobeNewswire / FDA press announcement (https://www.globenewswire.com/news-release/2026/07/01/3321045/0/en/fda-approves-first-gene-therapy-for-young-children-with-sickle-cell-disease.html)
- Vertex Pharmaceuticals / BioSpace press release (https://www.biospace.com/press-releases/fda-approves-first-gene-therapy-for-young-children-with-sickle-cell-disease)
- Xtalks (https://xtalks.com/fda-expands-casgevy-approval-for-children-as-young-as-2-with-sickle-cell-disease-4899/)
- TechTimes (https://www.techtimes.com/articles/319696/20260704/crispr-sickle-cell-therapy-now-cleared-children-starting-age-two.htm)
- HCPLive (https://www.hcplive.com/view/fda-expands-exa-cel-casgevy-gene-therapy-approval-2-years-scd-b-thalassemia)
- Respiratory Therapy (https://respiratory-therapy.com/products-treatment/pharmaceuticals/us-pharmaceuticals/fda-expands-casgevy-for-children-2-with-sickle-cell-disease/)